The FDA has approved Rocklatan, a once-daily IOP-lowering eye drop, for patients with open-angle glaucoma or ocular hypertension, Aerie Pharmaceuticals announced in a press release.
A fixed-dose combination of netarsudil and latanoprost, Rocklatan — previously known as Roclatan — is designed to target the trabecular meshwork, which is considered the main cause of elevated IOP, the release said.
FDA approval is based on data from two phase 3 trials in which Rocklatan demonstrated statistically significant IOP reduction compared with its two individual components.
Aerie plans to launch
Uncategorized